Magnetar Financial LLC Sells 8,572 Shares of Cellebrite DI Ltd. (NASDAQ:CLBT)

Magnetar Financial LLC decreased its position in shares of Cellebrite DI Ltd. (NASDAQ:CLBT) by 38.4% during the fourth quarter, HoldingsChannel reports. The fund owned 13,749 shares of the company’s stock after selling 8,572 shares during the quarter. Magnetar Financial LLC’s holdings in Cellebrite DI were worth $303,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. Quarry LP bought a new position in Cellebrite DI during the third quarter valued at $27,000. Advisors Asset Management Inc. boosted its stake in shares of Cellebrite DI by 130.5% during the third quarter. Advisors Asset Management Inc. now owns 3,077 shares of the company’s stock valued at $52,000 after purchasing an additional 1,742 shares during the period. R Squared Ltd purchased a new stake in shares of Cellebrite DI during the fourth quarter valued at $100,000. Polen Capital Management LLC purchased a new stake in shares of Cellebrite DI during the fourth quarter valued at $222,000. Finally, Victory Capital Management Inc. purchased a new stake in shares of Cellebrite DI during the fourth quarter valued at $234,000. Institutional investors own 45.88% of the company’s stock.

Cellebrite DI Stock Up 1.0 %

CLBT opened at $19.23 on Friday. Cellebrite DI Ltd. has a 52-week low of $10.25 and a 52-week high of $26.30. The company has a market cap of $4.61 billion, a P/E ratio of -13.83, a price-to-earnings-growth ratio of 4.27 and a beta of 1.52. The firm’s 50-day moving average price is $21.12 and its 200-day moving average price is $19.78.

Cellebrite DI (NASDAQ:CLBT) last posted its quarterly earnings data on Thursday, February 13th. The company reported $0.07 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.03). Cellebrite DI had a negative net margin of 70.54% and a positive return on equity of 58.70%. On average, research analysts anticipate that Cellebrite DI Ltd. will post 0.3 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on CLBT. JPMorgan Chase & Co. boosted their target price on shares of Cellebrite DI from $24.00 to $28.00 and gave the company an “overweight” rating in a research note on Tuesday, February 11th. Lake Street Capital upped their price objective on shares of Cellebrite DI from $17.00 to $26.00 and gave the stock a “buy” rating in a research note on Friday, February 14th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $28.00 price objective on shares of Cellebrite DI in a research note on Monday, March 10th. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Cellebrite DI has an average rating of “Buy” and an average price target of $23.43.

Cellebrite DI Company Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.